Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Dyadic International Earnings Call: Key Takeaways

Dyadic is transitioning to a commercial-stage company with modest initial sales, but faces liquidity constraints and slower-than-expected customer adoption despite technical validation from the Gates Foundation and partners.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthTotal revenue $449,000; Grant revenue down $538,000; R&D revenue down $188,000.
Mgmt ConfidenceHedging on timelines; admitted adoption is taking longer than originally anticipated.
Demand VisibilityIncreased sampling requests for transferrin; making to demand due to capital.
Order BookContractual $225,000 payment expected in Q4 from Ensigns commercial sale.
Margin TrendsCost of revenue decreased 63% to $375,000 following lower grant activity.
Op. LeverageLeveraging third-party distributors like IBT Bioservices to limit direct sales costs.
Vol vs PriceGrowth driven by initial direct sales and partner-led commercialization milestones.
Segment GrowthLife Sciences recorded first direct sales; Food/Nutrition added second commercial product.
New ClientsExpanded collaboration with BrightBio and Strive Nutrition for dairy proteins.
Capex & DebtEnded quarter with $6 million cash; $2.9 million raised in August.
RegulatoryDelayed 10-Q filing due to Microsoft Outlook issue; self-affirmed GRAS needed.
CommentaryShifting focus to larger strategic partnerships to leverage partner capital and infrastructure.
New LaunchesIBT Bioservices launched six research-use-only recombinant protein products.

Growth

Q3 revenue fell 61% to $449,000; nine-month revenue flat at $2.5 million.

Outlook

Targeting 10 to 200 metric tons of Alpha-lactalbumin supply for Strive Nutrition.

Risks

Management pivoted on adoption delays, citing regulatory hurdles and customer workflow integration timelines.

Source

The company's earnings call, NASDAQ: DYAI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Dyadic International Inc: key numbers

Share price
$0.3200Close, Nov 16
Market cap
$12.8M
Shares outstanding
40.09MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dyadic International Inc

All →
4:02 PM ET 10-Q
Financial Results ▶ Call

Dyadic International Q3 2026 Results: Net Loss of $1.36M, Loss Narrows

Dyadic International reported a net loss of $5.4 million for the nine months ended September 30, 2026, compared to $5.8 million in the prior year. The company is undergoing a strategic rebranding to Dyadic Applied BioSolutions, shifting focus from research to commercialized protein production platforms across life sciences and food sectors.

Key figure
Net loss $1.36M
11:57 AM ET 8-K
Financial Results

Dyadic International Financial Results

Dyadic International reported Q3 2026 financial results, highlighting its first direct commercial protein sales and expanded OEM distribution through IBT Bioservices. The company reported a net loss of $1.5M on revenue of $0.7M as it shifts focus toward larger strategic partnerships and licensing arrangements for its C1 and Dapibus production platforms.

Term
Q3 2026

“During the third quarter, we reached a key commercialization milestone for our animal-free protein portfolio, advancing market adoption through initial product sales and growing customer engagement across the food, life sciences, and biopharmaceutical sectors.”

Joe Hazelton, President and Chief Operating Officer

“Looking ahead, we are placing greater emphasis on larger strategic partnerships and collaborations, licensing and supply arrangements, and other potential transactions involving our platforms, products, and commercial programs.”

Joe Hazelton, President and Chief Operating Officer
5:28 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Dyadic International Nasdaq/NYSE Compliance Notice

Dyadic International received two deficiency notices from Nasdaq for failing to maintain a minimum bid price of $1.00 per share and a minimum Market Value of Listed Securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, until March 24, 2027, to regain compliance with both requirements.

Counterparty
The Nasdaq Stock Market LLC
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.